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The necessity of disposable biosensors for simple, rapid and inexpensive 
analysis in fields such as clinical, environmental or industrial has been highlighted 
over the past decade. In this way, screen-printed electrodes (SPEs) have been shown 
as inexpensive and reproducible devices for mass production of miniaturized 
biosensors [1-4]. These transducers, building by sequential layer deposition on the 
surface of ceramic or plastic substrates and curing steps, have been conventionally 
linked to the sensing element by adsorption, cross-linking, electropolymerization or 
covalent bonding. Bioelements are commonly immobilized after the printing and 
firing processes, because of the high temperatures reached during the curing step [5]. 
The immobilization procedure requires maintaining the initial properties of the 
enzyme intact. Thus, successful developments of biosensors largely rely on the cost 
and stability of the sensing elements [3]. 
 
Even if the above-mentioned immobilization procedures are efficient, they 
imply additional steps after fabrication of the screen-printed carbon electrodes 
(SPCEs), which extends the whole biosensor manufacturing. Screen-printing 
techniques also offer another attractive immobilization procedure consisting of 
printing the biological material. Enzymes, which are proteins able to catalyse specific 
chemical reactions in vivo, are by far the most commonly employed bioelements [1]. 
Enzymes can be integrated into the ink to form the sensing paste, which can be 
screen-printed resulting in biosensors fabricated by only one technology [6-8]. 
Undoubtedly, this immobilization procedure, which is known as automated 
immobilization, is particularly interesting for mass production of disposable 
biosensors. 
 
This work presents a simple way for preparing SPCEs modified with 
Horseradish peroxidase (HRP) for the determination of Levetiracetam (LEV). This 
second-generation antiepileptic drug (AEDs) has been previously determined using a 
SPCE-biosensor based on the immobilization of Horseradish peroxidase (HRP) by 
pyrrole electropolymerization [9] and covalent bonding [10] The screen-printing of 
HRP-containing ink (SPCHRPEs) offers a higher rapidity and simplicity in the 
manufacturing process of biosensors for LEV determination. 
 











 The human brain contains millions of nerve cells, each of which is connected 
to many others. Messages are passed between them by the extraordinarily rapid 
secretion of tiny packets of specialized chemicals known as neurotransmitters. When 
this happens coordinately, the brain integrates information from the outside world, 
enables us to perceive events around us, arranges our response to them by 
movements or other actions and also, organizes our social behavior. 
 
During an epileptic seizure the normal, quiet and integrated function of nerve 
cells is interrupted. Instead, they are stimulated in a disorderly manner and show an 
excessive electrical activity and as the seizure develops, more and more nerve cells 
become involved. 
 
There are numerous types of seizures and many potential causes of epilepsy. 
This illness is very common, affecting 3-4 per cent of people by the time they reach 
the age of 75. Epileptic seizures will stop with drug treatment for at least 60 per cent 





 AEDs are those which decrease the frequency and/or severity of seizures in 
people with epilepsy [12]. The first effective compound used for the treatment of 
seizures was potassium bromide, discovered serendipitously in 1850. 
 
In 1910, phenobarbital, which then was used to induce sleep, was found to 
have antiseizure activity and became the drug of choice for many years. Then, a 
number of similar medications were developed, including primidone, phenytoin, 
ethosuximide, clonazepam, diazepam or carmabazepine.  These anticonvulsants 
belong to the group of the first-generation AEDs and were the mainstays of seizure 
treatment until the 1990s, when newer AEDs with good efficacy, fewer toxic effects 
and better tolerability were developed. Among these new AEDs, so-called second-






 LEV is a white to off-white crystalline powder with a faint odor and a bitter 
taste. It is a pyrrolidone derivative (S-enantiomer of α-ethyl-2oxo-pyrrolidine 
acetamide) and its molecular weight is 170.2 g/mol (Figure 1) [14]. 





Figure 1.- Chemical structure of LEV 
 
 
This second-generation AED, licensed in the United States in 1999 [15] and 
approved for clinical use in 2002 [16], is one of the most used medicine in seizure 
clinics. Its effectiveness even when used alone may permit a broad spectrum of 
application [16]. It has been also successfully used in combination with other AEDs 
and potentiates the protective effects of these drugs without additional toxicity [17]. 
 
LEV absorption is independent of food and dosage. It is not metabolized in 
the liver and does not bind to blood proteins (less than 10 %). Metabolism is affected 
mainly by enzymatic hydrolysis, which takes place independently of cytochrome P-
450. Its plasma half-life is around 7 hours depending on the dose, being 95 % of drug 
elimination via urine [16]. 
 
 
2.3.- PHARMACOLOGY OF EPILEPSY 
 
 Pharmacology analyzes the breakdown and synthesis, biological activity, 
biological effects, and delivery of drugs [2]. 
 
Antiepileptic drug treatment provides excellent therapeutic effects in more 
than the two-third of the epileptic patients. AEDs influence the chronic 
hyperexcitability of the brain developed during the epileptogenesis. As an effect, it 
decreases the excitability and/or increases the inhibition of the pathological cells, 
which prevents the precipitation of the epileptic seizure (anticonvulsive effect) [18].  
 
 The anticonvulsive effect is only symptomatic and it doesn't cure the disorder. 
In the majority of the cases the treatment is prolonged for years or lifelong, that´s 
why issues such as toxicity, acute dose-dependent side effects, therapeutic 
compliance or convenience of medical administration must be borne in mind [19]. 
 
 Monotherapy is considered the ideal treatment for epilepsy, with a single 
AED. This is due to the reduction of side effects, no drug interactions, better 
compliance and lower costs. If monotherapy doesn’t work, it is switched to 
combination therapy with two or more drugs, which is known as polytherapy. The 
introduction of new compounds into the marketing has widened the choices for 









2.4.- THERAPEUTIC ANTIEPILEPTIC DRUGS MONITORING 
 
 Monitoring of plasma or serum concentrations of the older AEDs began to 
come into use in the late 1960s, initially as a research procedure that seemed as if it 
might find a future application in the management of epilepsy. This monitoring of 
plasma levels of AEDs was initiated in highly specialized services because very 
complex analytical methods such as gas chromatography, first, and liquid then, were 
used [21]. 
 
 At the present time monitoring of plasma AEDs concentrations appears to be 
requested a little less frequently than in the recent past and to be settling into a more 
balanced and cost-effective pattern of use after its initial phase of exuberant 
utilization. However, the reasons that led to monitor plasma levels of classical AEDs 
are still in force to justify the monitoring of the new generation ones [21].  
 
 The drugs used in the treatment of epilepsy have very low therapeutic index, 
so  there is very little difference between the toxic and the safe concentration. In 
addition, there is a wide inter-individual variability, genetically conditioned in the 
ability of each individual to metabolize AEDs. This fact combined with the influence 
of many factors, such as age or pregnancy, pathologies, such as kidney or liver 
failure and interactions, make the relationship between dose and therapeutic effects 
quite poor. Furthermore, epilepsy treatment is very prolonged, sometimes lifelong, so 
it is important to detect acute intoxication, prevent chronic toxicity and detect 
interactions with other drugs [20]. 
 
 Measuring of LEV serum levels is performed mainly for standard indications 
and for monitoring of levels in the elderly or those adults with impaired renal 
function of this nearly exclusive renal excreted drug. Potential monitoring of this 
drug during the third trimester of pregnancy may be beneficial. Clearance of LEV is 
increased in children, with one study showing an approximate 40% increase of 
clearance of the drug in 6-12 year-olds [17]. 
 
 
2.5.- ANALYTICAL DETERMINATIONS 
 
 A few analytical methods have been reported for the determination of LEV in 
pure drug, pharmaceutical dosage forms and biological samples using high-
performance liquid chromatography (HPLC) [22-25], gas chromatography (GC) 
[22], capillary electrophoresis (CE) [26] and HPLC/electrospray tandem mass 
spectrometry (HPLC-ESI/MS/MS) [27, 28]. 
 
 Most of them require pre-treatments of the samples such us solid-phase 
extraction, deproteinization by addition of organic solvents or formation of insoluble 
salts. Electrochemical procedures have been described as friendly-methodology that 








2.5.1.- Electrochemical determinations 
 
 Electroanalytical chemistry encompasses a group of qualitative and 
quantitative analytical methods based on the electrical properties of a solution of the 
analyte when it is made part of an electrochemical cell. These procedures have 
certain general advantages over other types of procedures, such as specificity for a 
particular oxidation state of an element, low capabilities of detection or 
instrumentation relatively inexpensive [29]. 
 
 Voltammetric methods are particularly convenient, accurate and precise in the 
analysis where the active ingredient, oxidizable or reducible, can be determined in 
the presence of inactive excipients. This procedure, which is based on the 
measurement of a current as a function of an applied potential, eliminates the time 
spent on the extraction of the species to determine and the losses incurred in the 
process, common operations on photometric and chromatographic methods, while 
the reliability and accuracy are at least comparable, if not better, than the methods 
mentioned [29]. 
 
 In recent years there has been a growing interest in the development of 
miniaturized electrodes in electrochemical instruments. Screen-printed technology 
has been shown as an attractive method for mass production of sensors at low cost. 
The technology has the advantages of design flexibility, process automation, good 
reproducibility, a wide choice of materials and reduced expense. These sensors 
recognize the chemical information present in the sample and transform it into an 
easily processable signal [30]. 
 
 When the receptor material has a biological origin, sensors are called 
biosensors. Enzymes are capable of catalyzing chemical reactions in a specific way. 
This specificity is the primary key for its use in the manufacturing of biosensors 
because enzymes have a much higher specificity than other chemical catalysts since 
only certain substrates are capable of access to the active sites of the enzyme. The 
utility of screen-printed technology to biosensors development has been widely 
shown in the last years, pointing out its promising introduction into the commercial 
market [31]. 
 
 Active agent LEV is susceptible of redox processes and, therefore, 
electrochemical procedures for its determination have been described. The use of 
electrochemical biosensors allows the analysis of the changes produced during this 
drug administration, which can have any influence in the therapy response and, 
therefore, be translated into variation or even suppression of it [20]. 
 
 The proposed methods combine miniaturized home-made screen-printed 
carbon electrodes (SPCEs) and a sensing element, Horseradish Peroxidase (HRP), 
leading to selective biosensors for LEV determination [9, 10]. Horseradish 
Peroxidase (HRP) utilizes hydrogen peroxide to oxidize a wide variety of organic 
and inorganic one-electron donor compounds, such as aromatic phenols, phenolic 
acids, indoles, amines and sulfonates [32]. The mechanism of peroxidase 
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SPCEs produced by the Electronalysis Research Group in the University of 
Burgos have been used [6]. 
 
All solutions were prepared with water purified with a Milli-Q device, which 
provided a resistivity of 18.2 M cm. 
 
HRP (EC 1.11.1.7., Sigma, Steinheim, Germany) was used as received. 
 
Stock standard solutions of LEV (kindly donated by UCB Pharma S.A.) were 
prepared by dissolving the adequate amount in water. 
 
50 mM phosphate buffer and 100 mM KCl (Merck, Darmstadt, Germany) 
solutions were used as supporting electrolyte. 1 M NaOH solutions (J.T. Baker, 





Electrochemical measurements were made by an Autolab electrochemical 
system with GPES software (Eco Chemie, Utrecht, The Netherlands). 
 




4.3.- SCREEN-PRINTED SENSORS AND BIOSENSORS MANUFACTURING 
 
 Screen-printed configurations of three electrodes (working, Ag/AgCl 
reference and counter electrode) were fabricated by sequential layer deposition onto 
0.5 mm thickness polyester films (HiFi Industrial Film, Dardilly, France). 
 
The printing process began with a carbon conducting ink, which is cured at 
60 ºC for 30 minutes. This first layer defined not only the conductive tracks, but also 
the carbon counter and working electrodes (SPCEs). Next, a Ag/AgCl ink was 
screen-printed over it and cured at 120 ºC for 20 minutes. In order to prevent the 
conducting paths from the solution, the dielectric ink was finally screen-printed and 
cured at 80 ºC for 30 minutes. 
 
HRP containing ink was prepared by thoroughly mixing of the carbon ink 
with HRP (0.4 % w/w) [6-8]. The mixture was sonicated for 20 minutes and 
immediately screen-printed on the working electrodes. The resulting biosensors were 
cured at 40 ºC for 1 hour in an oven (SPCHRPEs). The biosensors were kept at 4 ºC 
when not in use. 




4.4.- MEASURING PROCEDURE 
 
Cyclic and differential pulse voltammetric measurements were carried out in 
a cell containing 5 mL of a buffer solution, pH = 7, using different working 
electrodes (carbon paste, glassy carbon and screen-printed electrodes). 
 
Chronoamperometric measurements were made using (SPCHRPEs) in a cell 
containing 5 mL of buffer solution, pH 7, with constant stirring. A prepotential of 
500 mV vs Ag/AgCl screen-printed reference electrode (Ag/AgCl SPE) was applied 
during 30 seconds. Then, an operational potential of – 300 mV was applied vs 
Ag/AgCl SPE. Once a stable baseline was registered, hydrogen peroxide was added 
into the electrochemical cell to a final concentration of 1.9 mM. After reaching a 
steady-state current again, successive additions of LEV were performed. 
 
 
5.- ANÁLISIS Y DISCUSIÓN DE RESULTADOS 
 
5.1.- DETERMINACIÓN VOLTAMPEROMÉTRICA DE LEVETIRACETAM 
 
 El comportamiento electroquímico del fármaco antiepiléptico LEV en 
distintos electrodos se analizó utilizando diferentes técnicas voltamperométricas, en 
electrolito de soporte a diferentes valores de pH. 
 
 Se registraron voltamperogramas cíclicos de adiciones sucesivas de 100 µl de 
una disolución 10.0 mM de LEV empleando SPCEs en electrolito de soporte pH 7, 
entre -1.5 a 1.5 V vs Ag/AgCl SPE. 
 
 De igual manera, se realizaron experiencias mediante voltamperometría 
diferencial de impulsos mediante distintas adiciones de una disolución 10.0 mM de 
LEV, en electrolito de soporte pH entre - 1.5 a 1.5 V vs Ag/AgCl SPE. En este caso 
se utilizaron electrodos de carbono vitrificado, pasta de carbono, SPCEs y SPAuEs.  
 
 Desafortunadamente no se obtuvo respuesta electroquímica del LEV en 
ninguno de los casos (Figura 3) por lo que se propuso el empleo de biosensores 
amperométricos para la determinación de este principio activo. 
 
 
5.2.- DETERMINACIÓN DE LEVETIRACETAM UTILIZANDO BIOSENSORES 
ELECTROQUÍMICOS 
 
 Como se ha mencionado anteriormente, la concentración de este principio 
activo en una disolución se puede relacionar con la intensidad registrada 
cronoamperométricamente utilizando biosensores basados en el enzima HRP de 
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Figura 4.- Voltamperograma cíclico registrado con un SPCHRPE en una disolución 100 mM 
de KCl a 50 mVs-1. 
 
 
 En la figura 5 se muestra un cronoamperograma registrado en un biosensor 
SPCHRPE en las condiciones óptimas de las variables experimentales. Para la 
obtención de dicho cronoamperograma, se realizaron sucesivas adiciones de 50 µl de 
una disolución 0.5 M de LEV, tras la estabilización de la señal debida a la reducción 
del agua oxigenada utilizado en la regeneración del enzima. 
 
 En las condiciones optimizadas de las variables experimentales se realizaron 
experiencias de control utilizando electrodos serigrafiados de carbono sin modificar 
con el enzima HRP, en los que no se obtuvo respuesta alguna, pudiéndose comprobar 
así la selectividad del biosensor desarrollado hacia el analito objeto de estudio. 
 
 
5.2.1.- Validación del método  
 
 La validación de un método analítico se define como el proceso basado en 
estudios sistemáticos de laboratorio, mediante el cual se pone de manifiesto que 
dicho método posee unas características de funcionamiento adecuadas para la 
aplicación que se le quiere dar. Dichas características de funcionamiento se 
determinan a través de la precisión, la capacidad de detección, la exactitud, el 
intervalo dinámico, la sensibilidad, la selectividad y la robustez, los llamados 
parámetros de calidad. La precisión, la capacidad de detección y la exactitud se 
consideran parámetros primarios ya que su impacto sobre la calidad de un método 
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Tabla 1.- Parámetros de calibración, obtenidos con distintos métodos de regresión, para 








Nº de datos 8 8 6 
Pendiente 0.09 0.08 0.08 
Término independiente 0.48 0.81 0.57 
Coeficiente de determinación (R2) 0.99 0.99 0.99 
Desviación estándar residual 0.13 - 0.09 
Nº de datos 5 5 5 
Pendiente 0.08 0.08 0.08 
Término independiente -0.01 -0.07 -0.01 
Coeficiente de determinación (R2) 0.98 0.94 0.98 
Desviación estándar residual 0.09 - 0.09 
Nº de datos 9 9 8 
Pendiente 0.07 0.08 0.07 
Término independiente -0.16 -0.26 -0.24 
Coeficiente de determinación (R2) 0.99 0.99 0.99 




▪ Capacidad de detección 
 
 Se define la capacidad de detección como la concentración o la cantidad de 
analito derivada de la medida más pequeña y que puede detectarse con una certeza 
razonable mediante un determinado procedimiento analítico. Es muy habitual, y cada 
día aún más, analizar componentes de muestras a niveles bajos de concentración. En 
estos casos, hay que discriminar entre muestras en las que se detecta analito y 
muestras en las que no. Además, una vez detectado el analito, se ha de fijar un límite 
a partir del que poder estimar cuantitativamente y de forma fiable su concentración 
[36].  
 
 A menor ruido y mayor sensibilidad del método, mayor será también la 
capacidad de discriminación entre el blanco y las muestras o patrones a baja 
concentración. Dado que todas las medidas experimentales están siempre sujetas a 
errores, será necesario recurrir siempre a criterios estadísticos y de probabilidad. Al 
determinar la presencia o la ausencia de analito en una muestra se han de evitar dos 
tipos de errores [36]: 
 
 - Los falsos positivos (α), denominados errores de tipo α, que consisten en 
dictaminar la presencia de analito cuando en realidad la muestra no lo contiene. 
 
 - Los falsos negativos (β), denominados errores de tipo β, en los que se 
determina que no hay analito cuando en realidad la muestra lo contiene. 
 




 Este procedimiento analítico fue también caracterizado mediante su 
capacidad de detección, teniendo en cuenta α y β [18, 38]. En el cálculo de este 
índice de calidad también se precisaron regresiones validadas entre la concentración 
y la señal analítica, construidas en el rango de 4.8 a 40.5 mM [39].  
 
 El valor mínimo de concentración detectable, 1.6 ± 0.3 mM (α = β = 0.05; n = 
3), fue menor que el valor del primer estándar utilizado para construir las curvas de 
calibrado 4.8 mM. Por lo tanto, desde un punto de vista analítico, este último valor se 
estimó como capacidad de detección del método [40]. 
 
 
▪ Exactitud del método: Determinación de levetiracetam en fármacos comerciales 
 
La IUPAC define la exactitud como el grado de concordancia entre el 
resultado de una medida y el valor real del mensurando. En una nota asociada a esta 
definición se añade que es un concepto cualitativo utilizado para describir el error 
asociado a un resultado y para ello hace falta un parámetro que permita medir 
cuantitativamente la exactitud. Este parámetro es el error, que se define como la 
diferencia entre el resultado de la medida y el valor real del mensurando. Estas 
definiciones son más bien estadísticas, donde aparece el valor verdadero o real como 
últimas referencias. Desde el punto de vista metrológico se habla más bien de 
trazabilidad, sustituyendo estos valores que no son conocidos por los valores de 
referencia de patrones y materiales de referencia certificados [36]. 
 
 La exactitud de un método analítico se puede demostrar de diversas formas, 
pero no todas poseen la misma categoría metrológica ni se pueden aplicar con la 
misma facilidad. Las más utilizadas son el empleo de materiales de referencia 
certificados, la comparación con un método de referencia, el análisis de muestras 
adicionadas y el análisis de muestras manufacturadas con un contenido de analito 
conocido, como es este caso [36]. 
  
 De este modo, finalmente los biosensores basados en el enzima HRP se 
emplearon para analizar el contenido de LEV en un fármaco comercial de marca 
registrada Keppra. 
 
 Se disolvió una gragea de 1000 mg en 10 ml de agua, se sometió a un baño de 
ultrasonidos y, por último, se centrifugó. Esta muestra se analizó mediante el método 
de interpolación en una curva de calibrado [41]. 
 
 Para ello, se registraron varios cronoamperogramas, utilizando SPCHRPEs, en 
las condiciones óptimas de las variables experimentales. Siguiendo el procedimiento 
descrito anteriormente, una vez estabilizada la señal cronoamperométrica se añadió a 
la celda electroquímica una disolución de agua oxigenada 1.9 mM, y al estabilizarse 
nuevamente esta señal de reducción, se añadieron 200 µl de la disolución del 
fármaco comercial a la celda electroquímica registrándose una señal de oxidación 
(Figura 7). 





Figura 7.- Cronoamperograma registrado para la determinación de LEV en disolución de 
una gragea de 1000 mg de fármaco comercial utilizando un SPCHRPE, en las condiciones 
optimizadas: pH = 7, Ew = - 0.3 V vs Ag/AgCl SPE y CH2O2  = 1.9 mM. 
 
 
 Dicha señal de oxidación está relacionada con la concentración de LEV en el 
fármaco comercial, por lo que interpolando este valor en las curvas de calibración 
anteriormente obtenidas (Figura 5) se obtiene el valor de concentración deseado. La 
tabla 2 muestra los buenos resultados obtenidos con este procedimiento en términos 
de RSD y de intervalo de confianza para la media, lo que confirma su exactitud. 
 
 
Tabla 2.- RSD e intervalo de confianza para la media de los valores de LEV obtenidos en 
las muestras del fármaco, utilizando SPCHRPEs. 
 
 
Cantidad de LEV 
en las grageas (mg) 




confianza al 95% 
































 Con los datos recogidos en este trabajo se puede concluir que: 
 
• El empleo de biosensores construidos a partir de electrodos de carbono 
serigrafiados con el enzima HRP supone una técnica sencilla, reproducible y 
económica para la detección cronoamperométrica de LEV. 
 
•  Los análisis mediante cronoamperometría están muy influenciados por variables 
experimentales como la concentración de peróxido de hidrógeno, el potencial de 
trabajo y el pH del medio de análisis. 
• Las condiciones óptimas de las variables experimentales son 7, - 0.3 V vs. Ag/AgCl 
SPE y 1.9 mM para el pH, el potencial de trabajo y la concentración de peróxido de 
hidrógeno, respectivamente. 
• La reproducibilidad del método propuesto asociada a las pendientes de las curvas 
de calibración en términos de RSD, en el intervalo de concentración de 4.8 a 40.5 
mM, fue de 7.3% (n = 3).  
• La capacidad de detección obtenida para el LEV en las condiciones óptimas de las 
variables experimentales fue de 4.8 mM (α = β = 0.05; n = 3). 
• La reproducibilidad de métodos similares para la determinación de LEV asociada a 
las pendiente de las rectas de calibración obtenidas en trabajos anteriores, 6.2% y 
7.7%, es del mismo orden que la obtenida con el procedimiento aquí desarrollado. 
• Por el contrario, las capacidades de detección de dichos métodos presentan valores 
ligeramente inferiores, del orden de 10-5M para α = β = 0.05. Este hecho puede ser 
atribuido a que los SPCHRPEs utilizados han sido almacenados durante más de un 
año, lo que sin duda alguna conlleva la pérdida de actividad enzimática. Sin 
embargo, esto pone de manifiesto la idoneidad de los mismos para su utilización en 
la determinación de LEV sin pérdida significativa de sensibilidad, incluso después de 
largos períodos de tiempo desde su fabricación, lo que facilitaría su 
comercialización. 
• Los dispositivos empleados tienen carácter desechable, sin embargo, han permitido 
realizar varias medidas con un mismo SPCE obteniéndose resultados satisfactorios. 
• Los biosensores utilizados han demostrado su viabilidad para realizar análisis 
cuantitativos de LEV en muestras complejas, como el fármaco comercial Keppra. 
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